How to Get Mounjaro in Maryland

What Is Mounjaro and Why Is It Prescribed?

Mounjaro is the brand name for tirzepatide, a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Eli Lilly. The FDA approved it in May 2022 for glycemic control in adults with type 2 diabetes, and later approved tirzepatide under the brand name Zepbound for chronic weight management.

Tirzepatide works by activating both GIP and GLP-1 receptors simultaneously. This dual mechanism slows gastric emptying, increases insulin secretion in a glucose-dependent manner, and suppresses glucagon release 1. The result is improved blood sugar control alongside significant weight reduction.

In the SURPASS-2 trial (N=1,879), patients randomized to tirzepatide 15 mg achieved a mean HbA1c reduction of 2.37% at 40 weeks, compared with 1.86% for semaglutide 1 mg 1. Weight loss in the same group averaged 12.4 kg versus 6.2 kg with semaglutide. These differences were statistically significant (P<0.001 for both endpoints). The SURMOUNT-1 trial (N=2,539) later demonstrated that tirzepatide 15 mg produced 22.5% mean body weight reduction in adults with obesity at 72 weeks 2.

For Maryland residents, the practical question is straightforward: how do you actually get a prescription filled? The answer depends on your insurance status, your prescriber, and which pharmacy you use.

Who Can Prescribe Mounjaro in Maryland?

Any licensed Maryland prescriber with active prescriptive authority can write a tirzepatide prescription. That includes physicians (MDs and DOs), nurse practitioners (NPs), and physician assistants (PAs).

Maryland grants NPs full practice authority under the Maryland Nurse Practice Act, meaning NPs can evaluate, diagnose, and prescribe Schedule II through V controlled substances and non-controlled medications independently after meeting the state's required supervised practice period 3. Tirzepatide is not a controlled substance, so any NP with an active Maryland license and national certification can prescribe it without physician oversight. PAs in Maryland prescribe under a delegation agreement with a supervising physician, but this arrangement does not limit their ability to prescribe Mounjaro.

The American Association of Clinical Endocrinology (AACE) 2023 consensus statement notes that "tirzepatide should be considered as a first-line injectable option for patients with type 2 diabetes who require greater glycemic and weight reduction than oral agents alone can provide" 4. Primary care providers, endocrinologists, obesity medicine specialists, and internal medicine physicians all write tirzepatide prescriptions regularly. You do not need a specialist referral in Maryland.

Getting Mounjaro Through Telehealth in Maryland

Maryland authorizes telehealth prescribing for non-controlled medications, and tirzepatide qualifies. Several platforms operate in the state, connecting patients with licensed prescribers who can evaluate candidacy, order labs, and transmit prescriptions to a pharmacy of the patient's choosing.

A typical telehealth visit follows a defined workflow. The patient completes a medical intake form that captures weight, height, BMI, medical history, current medications, and contraindications. A licensed provider reviews the intake, conducts a synchronous video or audio visit (Maryland requires a real-time component for initial prescriptions under COMAR 10.32.05), and determines whether tirzepatide is appropriate 5.

The provider then sends an electronic prescription to either a retail pharmacy or a licensed 503A compounding pharmacy. Turnaround from evaluation to prescription is often 24 to 72 hours. Shipping adds another 2 to 5 business days for compounded formulations, while brand-name Mounjaro at a retail pharmacy is typically available for pickup the same day or next day, assuming no prior authorization delays.

Maryland's telehealth parity law (Md. Code, Health-General §15-139) requires commercial insurers to cover telehealth-delivered services at the same rate as in-person services. This means your insurer cannot deny coverage of the visit simply because it occurred over video. The medication itself, however, remains subject to the plan's formulary and prior authorization requirements.

Labs and Clinical Requirements Before Starting

Most prescribers require baseline labs before initiating tirzepatide. These are not mandated by Maryland state law, but they reflect standard-of-care practice as outlined by the AACE and the American Diabetes Association (ADA).

The ADA's 2024 Standards of Care recommend obtaining HbA1c, fasting glucose, a comprehensive metabolic panel (CMP), and a lipid panel before starting any GLP-1 receptor agonist 6. A thyroid-stimulating hormone (TSH) level is also commonly ordered because tirzepatide carries a boxed warning about medullary thyroid carcinoma (MTC) risk observed in rodent studies, making it contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 7.

A renal function panel (BUN and creatinine) helps guide dosing decisions, as patients with severe gastrointestinal side effects may be at risk for dehydration-related acute kidney injury. The FDA label specifically warns about this risk in post-marketing data 7.

Expect the following labs:

• HbA1c (or fasting glucose if prescribing for weight management only)
• Comprehensive metabolic panel including liver enzymes, creatinine, electrolytes
• Lipid panel (LDL, HDL, triglycerides, total cholesterol)
• TSH to screen for thyroid dysfunction
• Pregnancy test for women of reproductive age (tirzepatide is not recommended during pregnancy)

Some telehealth platforms include at-home lab kits or partner with national lab networks like Quest Diagnostics and Labcorp, both of which operate multiple draw sites across Maryland. Results typically return within 2 to 3 business days.

Maryland Medicaid and Insurance Coverage

Maryland Medicaid covers brand-name Mounjaro for its FDA-approved indication of type 2 diabetes. Coverage requires prior authorization (PA). Off-label use for weight management alone is generally not covered under Maryland Medicaid, though Zepbound (the obesity-specific tirzepatide brand) may be covered under certain managed care organization (MCO) plans 8.

The prior authorization process for Maryland Medicaid typically requires:

• A confirmed diagnosis of type 2 diabetes (ICD-10 code E11.x)
• Documentation of HbA1c at or above 7.0% despite lifestyle modification
• Failure of or contraindication to metformin (first-line therapy per ADA guidelines)
• Prescriber attestation that the patient does not have a history of pancreatitis, MTC, or MEN2

For commercial insurance, coverage varies by plan. Eli Lilly's Mounjaro Savings Card reduces copays to as low as $25 per fill for commercially insured patients, though this program excludes government-funded insurance 9. Check with your specific plan's formulary.

Dr. Irl Hirsch, professor of medicine at the University of Washington, has stated: "The prior authorization burden for GLP-1 receptor agonists remains the single largest barrier to patient access in the United States, adding weeks of delay to medications with strong evidence of benefit" 10.

Processing time for Maryland Medicaid PAs is typically 3 to 5 business days. If denied, your prescriber can file a peer-to-peer review or a formal appeal within 30 days.

503A Compounding Pharmacies in Maryland

Maryland licenses 503A compounding pharmacies under the Maryland Board of Pharmacy. These pharmacies can prepare tirzepatide formulations based on a valid patient-specific prescription from a licensed prescriber. They cannot produce copies of commercially available drugs unless a documented shortage exists or the prescriber certifies a clinical need for an altered formulation 11.

Compounded tirzepatide is not the same product as brand-name Mounjaro. The FDA does not review compounded medications for safety, efficacy, or manufacturing consistency the way it reviews commercially manufactured drugs 11. Patients choosing compounded tirzepatide should verify that their pharmacy holds a current Maryland Board of Pharmacy license and complies with USP <797> sterile compounding standards.

Several Maryland-based and out-of-state 503A pharmacies ship compounded tirzepatide to Maryland addresses. Cold-chain shipping (2°C to 8°C) is standard for injectable peptides. Confirm that the pharmacy uses validated temperature-controlled packaging before placing an order.

Pricing for compounded tirzepatide typically ranges from $150 to $500 per month depending on dose, pharmacy, and whether the prescription includes bacteriostatic water and syringes. Brand-name Mounjaro carries a list price of approximately $1,023 per month without insurance.

Dosing, Titration, and What to Expect

Tirzepatide follows a structured titration protocol. The starting dose is 2.5 mg injected subcutaneously once weekly for the first four weeks. This initial phase is not a therapeutic dose. It allows the gastrointestinal tract to adapt to the medication.

After four weeks, the dose increases to 5 mg weekly. From there, the prescriber may increase by 2.5 mg increments every four weeks based on tolerability and clinical response, up to a maximum of 15 mg weekly 7.

The most common side effects are gastrointestinal: nausea (reported in 12% to 18% of SURPASS trial participants), diarrhea (12% to 17%), decreased appetite, vomiting, and constipation 1. These effects are typically mild to moderate and tend to diminish after the first 4 to 8 weeks.

Injection sites include the abdomen, thigh, or upper arm. Rotate injection sites with each dose. The Mounjaro KwikPen and single-dose vial both deliver the same formulation. The KwikPen is pre-filled and does not require manual dose measurement.

Patients using compounded tirzepatide from vials will need to draw the correct dose using an insulin syringe. Your pharmacy or prescriber should provide detailed instructions for reconstitution (if lyophilized) and injection technique.

In SURPASS-2, participants taking tirzepatide 15 mg lost an average of 12.4 kg (27.3 lb) at 40 weeks 1. Weight loss typically becomes noticeable within the first 8 to 12 weeks and continues through the first year.

Transferring a Mounjaro Prescription to Maryland

If you are relocating to Maryland or splitting time between states, your existing tirzepatide prescription can be transferred. Maryland accepts prescription transfers from other U.S. states for non-controlled medications. Your current pharmacy can initiate a transfer to any Maryland retail or specialty pharmacy.

For telehealth patients, the prescribing platform must hold a license to practice in Maryland. If your current telehealth provider is not licensed in the state, you will need to establish care with a Maryland-licensed prescriber. This usually requires a new intake visit but does not require repeating labs if recent results (within 90 days) are available.

Compounded tirzepatide prescriptions present a different situation. Because compounded medications are patient-specific and pharmacy-specific, you may need a new prescription sent to a Maryland-licensed 503A pharmacy rather than transferring the original. Ask your prescriber to send a new Rx to the pharmacy of your choice.

Timeline: From First Visit to First Injection

Understanding the full timeline helps set realistic expectations. Here is a typical sequence for a Maryland resident starting Mounjaro through telehealth:

• Day 1: Complete online intake, schedule evaluation
• Days 2 to 3: Synchronous telehealth visit with licensed prescriber
• Days 3 to 5: Lab work completed at local draw site (if not already available)
• Days 5 to 8: Lab results reviewed, prescription transmitted
• Days 8 to 10: Medication arrives (compounded, shipped) or is ready for pickup (brand, retail pharmacy)
• Days 8 to 15: If prior authorization is required, add 3 to 5 business days

Total elapsed time ranges from 5 business days (cash-pay, no PA needed, labs on file) to 15 business days (insurance with PA, new labs required). Some patients receive their medication faster. Delays most commonly stem from prior authorization or lab scheduling.

Safety Considerations and Contraindications

Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. The drug carries an FDA boxed warning based on thyroid C-cell tumor findings in rodent studies, though no causal link has been confirmed in humans 7.

Additional contraindications and precautions include:

• History of pancreatitis: Discontinue if pancreatitis is suspected; do not restart
• Severe gastrointestinal disease: Gastroparesis or inflammatory bowel disease may worsen
• Diabetic retinopathy: Rapid glucose improvement can temporarily worsen diabetic retinopathy; monitor accordingly
• Pregnancy: Not recommended; discontinue at least 2 months before a planned pregnancy due to the long washout period
• Gallbladder disease: GLP-1 receptor agonists are associated with increased cholelithiasis risk

The ADA's 2024 Standards of Care state: "Patients initiating GLP-1 receptor agonists should be counseled on the signs and symptoms of pancreatitis and instructed to seek medical attention immediately if severe abdominal pain occurs" 6.

Report any persistent vomiting, severe abdominal pain, or signs of allergic reaction (rash, swelling, difficulty breathing) to your prescriber immediately.